Cautious Optimism for DENTSPLY SIRONA Amid Recovery and Challenges: Hold Rating Maintained with Price Target at $17

Evercore ISI analyst Elizabeth Anderson CFA has maintained their neutral stance on XRAY stock, giving a Hold rating today.

Elizabeth Anderson CFA’s rating is based on the observation that while DENTSPLY SIRONA is showing signs of recovery in its dental segment post-COVID, there are still significant challenges to overcome. The company faces ongoing macroeconomic pressures and tariff impacts, which are affecting its financial performance. Despite these hurdles, there is optimism due to positive sentiment outside the US and operational improvements underway.
However, Anderson remains cautious and prefers to wait for more concrete evidence of financial gains from these efforts before upgrading the rating. The expectation is that clearer signs of positive organic growth and resolution of current issues, such as the Byte overhang, might emerge by late 2025 or 2026. Until then, the recommendation remains at Hold, with a price target adjustment to $17, reflecting a cautious but optimistic outlook.